Positron emission tomography for staging and management of malignant melanoma (Q34600508)

3 August 2017

1 reference

title

Positron emission tomography for staging and management of malignant melanoma (English)

1 reference

positron emission tomography

3 August 2017

main subject

1 reference

Prichard RS

1

1 reference

3 August 2017

Hill AD

series ordinal

2

1 reference

3 August 2017

Skehan SJ

series ordinal

3

1 reference

3 August 2017

O'Higgins NJ

series ordinal

4

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

British Journal of Surgery

3 August 2017

published in

1 reference

3 August 2017

volume

89

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

389-396

1 reference

3 August 2017

cites work

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Malignant melanoma in the 1990s: the continued importance of early detection and the role of physician examination and self-examination of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

21 January 2018

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Epidemiology of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

METASTATIC MELANOMA. A CLINICOPATHOLOGICAL STUDY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Effectiveness of positron emission tomography for the detection of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

PET in oncology: will it replace the other modalities?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

Cost-effectiveness of PET imaging in clinical oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.0007-1323.2002.02059.X

10.1046/J.0007-1323.2002.02059.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference